Key Highlights

  • Third-quarter Net Income reached USD 3.9 million, compared with a USD 8.8 million net loss a year earlier, even though operations lost USD 6.3 million.
  • Fair value gains of USD 7.5 million on warrants and USD 3.4 million on Derivatives generated total other income of USD 10.3 million.
  • Revenue totaled USD 56 thousand against USD 15 thousand, while Research and Development spending increased to USD 4.4 million from USD 3.5 million.
  • Cash stood at USD 9.9 million on September 30, 2026, against a stockholders' Deficit of USD 14.8 million and a nine-month operating cash outflow of USD 11.7 million.

Accounting Gains Lift a Quarter Otherwise in Loss

Clene (NASDAQ:CLNN) lodged its 10-Q on November 4, 2026 covering the quarter ended September 30. Product sales came to USD 43 thousand and royalties to USD 13 thousand, while operating costs of USD 6.4 million produced an operating shortfall of USD 6.3 million. The USD 3.9 million profit was delivered by USD 10.3 million of other income, primarily non-cash revaluations of Warrant and derivative liabilities. Diluted EPS was USD 0.05 and basic EPS USD 0.30, compared with a loss of USD 0.85 a year earlier. Without those Revaluation gains, the Business would still be reporting a loss.

Nine-Month Deficit, January Financing and Warrant Terms

The company develops drug candidates based on nanocrystals using a clean-surface nanotechnology platform. Across nine months its net loss was USD 17.6 million, or USD 1.42 per share, against USD 16.9 million, or USD 1.77. That period absorbed a USD 4.6 million loss tied to the first recognition of Equity from a January 2026 public offering that included Series A warrants for 1.2 shares each and Series B warrants for 2.8 shares each. Net proceeds from stock and warrants came to USD 16.7 million. Shares outstanding increased to 14,213,981 from 10,849,974 at the close of 2025.

Limited Cash, Convertible Debt and Liquidity Exposure

Nine-month operating cash use of USD 11.7 million means USD 9.9 million of cash would not sustain a full year at that rate. Current liabilities totaled USD 17.1 million, including USD 8.0 million of convertible notes and USD 5.0 million of notes payable, while warrant and derivative liabilities stand at USD 11.0 million. The filing names going-concern considerations and plans to raise Capital among its forward-looking subjects. Because the share count is small and trading thin, a few transactions can move the price, spreads can be wide and quoted moves can reverse. Fair Value gains can also reverse as the share price changes.

Where Things Stand

Accounting gains, not operations, produced the profit. Clene (NASDAQ:CLNN) lost USD 6.3 million from operations during the quarter, yet remeasuring warrant and derivative liabilities contributed USD 10.9 million of non-cash gains, which left net income at USD 3.9 million. The nine-month figures reveal the underlying position, a net loss of USD 17.6 million. With USD 9.9 million in cash and a USD 14.8 million stockholders' deficit, new financing looks central to the outlook. Next checkpoints are the cash burn pace, convertible note maturities and clinical updates, none of which are detailed in this extract. Investors can track whether the revaluation gains reverse in coming quarters, since they depend on share price movement.